Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Politics, Policy & Law

Supreme Court mifepristone ruling slams lid on Pandora’s box

Court unanimously rejects notion that any physician can sue FDA over any regulatory action

June 13, 2024 11:07 PM UTC

The Supreme Court’s unanimous decision, released Thursday, to dismiss an attempt to overturn FDA’s decisions on access to the abortion drug mifepristone marks the end of a legal odyssey that threatened to undermine the agency’s ability to regulate medicines.

The ruling shuts a Pandora’s box that Judge Matthew Kacsmaryk of the U.S. District Court for the Northern District of Texas opened in April 2023 when he ruled that physicians with remote and largely imaginary connections to the approval and regulation of mifepristone had standing to sue the agency...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article